Ipamorelin vs Tesamorelin

A selective growth hormone secretagogue that stimulates pulsatile GH release from the pituitary without significantly affecting cortisol, prolactin, or appetite.

An FDA-approved growth-hormone-releasing hormone analogue for HIV-associated lipodystrophy, used off-label for visceral fat reduction and metabolic health.

Ipamorelin binds the ghrelin receptor (GHSR-1a) in the pituitary, triggering growth hormone release. Unlike earlier secretagogues such as GHRP-6, ipamorelin is highly selective and does not induce hunger or stimulate cortisol.

Tesamorelin is a stabilised GHRH analogue with a longer half-life than sermorelin. It selectively reduces visceral adipose tissue (VAT) while preserving subcutaneous fat and lean mass.

200–300 mcg, 1–3 times daily (research protocols)

1–2 mg subcutaneous daily

~2 hours

~26 minutes

Subcutaneous

Subcutaneous

research-only

approved

£21 · £4.2/mg via Peptides UK

Not yet listed